Daxor Wins Patent for Remote Blood Volume Monitor, Expanding Diagnostic Capabilities
DXR sits 40% above its 52-week low of $7.185 on light trading volume (0.1× avg).
Summary
Daxor Corporation has secured a U.S. patent for a breakthrough remote blood volume monitor. This technology enables continuous, remote tracking of blood volume status using wearable sensors, a significant expansion of their diagnostic capabilities. This follows recent news of Daxor showcasing its portable BVA and launching new BVA programs. The patent is transformative, shifting blood volume management from episodic to proactive care, which could significantly improve outcomes for patients with chronic conditions like heart failure and expand Daxor's market.
At the time of this announcement, DXR was trading at $10.06 on NASDAQ in the Life Sciences sector. The 52-week trading range was $7.19 to $14.76. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.